he pancreatic cancer is 3rd leading cause of cancer death in the USAccording to National Cancer Institute, and one of the deadliest institutions.. The five-year survival rate for pancreatic cancer is only 13%, but this drops to 3% if the cancer spreads to other parts of the body.
In this situation where solutions are urgently needed, Food and Drug Administration (FDA) Awarded in October revolutionary medicinethe biotechnology company that sponsors the drug, A revolutionary new rapid review aimed at getting promising medicines to patients faster than ever before.
This drug, like other drugs selected as “therapeutic drugs for pancreatic cancer,”The Secretary’s National Priority Vouchers will test whether they can accelerate the development of innovative treatments Experts say it will not undermine the rigor of the agency’s review.
Authoritarians don’t like this
The practice of professional and critical journalism is a fundamental pillar of democracy. That is why it bothers those who believe that they are the owners of the truth.
The FDA said the program will shorten drug reviews from one year to as little as one month, allowing companies that receive FDA approval to market their drugs more quickly.
About The Author
